Abstract: This invention provides an HLA class I-expressing non-human animal that can be prepared efficiently in a simple manner within a short period of time, in which the transgene copy number to be introduced thereinto and the integration site of transgene are regulated, and in which the expression level of the transgene and the site of expression thereof are regulated. The invention also provides a method for preparing such non-human animal. In such HLA class I gene knock-in non-human animal, an artificial chimeric gene encoding an artificial chimeric protein comprising a protein composed of ?2 microglobulin, HLA class I ?1 and ?2 regions, and an MHC class I ?3 region of a non-human animal ligated in such order from the N terminus is expressed under the control of a transcription regulatory region of ?2 microglobulin gene of the non-human animal.

Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.

Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.

Abstract: This invention relates to an immunomodulator comprising, as an active ingredient, (S)—N-(4-amino-5-(quinolin-3-yl)-6,7,8,9-tetrahydropyrimido[5,4-b]indolizin-8-yl)acrylamide represented by Formula (I) or a salt thereof and a pharmaceutical composition for the prevention or treatment of a disease that can be ameliorated via immunomodulation.

Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 5 linked CTL epitopes is obtained by linking 5 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.

Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 4 linked CTL epitopes is obtained by linking 4 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.

Abstract: This invention provides an HLA class I-expressing non-human animal that can be prepared efficiently in a simple manner within a short period of time, in which the transgene copy number to be introduced thereinto and the integration site of transgene are regulated, and in which the expression level of the transgene and the site of expression thereof are regulated. The invention also provides a method for preparing such non-human animal. In such HLA class I gene knock-in non-human animal, an artificial chimeric gene encoding an artificial chimeric protein comprising a protein composed of ?2 microglobulin, HLA class I ?1 and ?2 regions, and an MHC class I ?3 region of a non-human animal ligated in such order from the N terminus is expressed under the control of a transcription regulatory region of ?2 microglobulin gene of the non-human animal.

Abstract: This invention provides a cancer antigen peptide that can be administered to a wide range of cancer patients in the form of a peptide vaccine for cancer without the need for HLA typing and regardless of the HLA types of patients. Such peptide having 5 linked CTL epitopes is obtained by linking 5 CTL epitope peptides selected from among CTL epitope peptides derived from tumor antigen molecules that are reported to have the capacity for CTL induction via linkers.

Abstract: An antimicrobial laminate excelling in the ability to effect gradual release of an antimicrobial agent and providing an antimicrobial action evenly and bags and other containers using the antimicrobial laminate are disclosed. A substratal film 24 impervious to steam is provided on one side of a substratal film proper 22 of paper with a gas-barriering layer 23 of aluminum foil. An antimicrobial film 21a pervious to steam is formed by sequentially superposing an adhesive agent layer (AITC regenerating layer) 16a containing an AITC inclusion cyclodextrin compound 15 (fine powder), a steam-pervious film 17a having a fine powder of silica gel dispersed therein, an adhesive agent layer 16b identical in construction with the adhesive agent layer 16a, and a sealant material 17b of steam-pervious film in the order mentioned. An antimicrobial layer 121 is constructed by adhesively superposing the substratal film 24 and the antimicrobial film 21a through the medium of the adhesive agent layer 16a.